Search

Your search keyword '"Olga I. Maslova"' showing total 3 results
Start Over Author "Olga I. Maslova"
3 results on '"Olga I. Maslova"'

1. NEUROGENETIC ASPECTS OF PERINATAL HYPOXIC-ISCHEMIC AFFECTIONS OF THE CENTRAL NERVOUS SYSTEM

Author

George A. Karkashadze, Kirill V. Savostianov, Svetlana G. Makarova, Leyla S. Namazova-Baranova, Olga I. Maslova, and Galina V. Yatsyk

Subjects
perinatal hypoxic-ischemic brain affections, newborns, perinatal brain affections, neurogenetics, prematurity neurogenetics, prematurity epigenetics, epigenetics of perinatal brain affections, Pediatrics, RJ1-570
Abstract

Neurogenetics is a thriving young science greatly contributing to the generally accepted concept of the brain development in health and disease. Thereby; scientists are not only able to highlight new key points in traditional ideas about the origin of diseases; but also to completely rethink their view on the problem of pathology development. In particular; new data on neurogenetics of perinatal affections of the central nervous system (CNS) has appeared. Genetic factors in varying degrees affect perinatal hypoxic-ischemic CNS affections. Prematurity determination stays the most studied among them. Nevertheless; there is increasing evidence of significant epigenetic regulations of neuro-expression caused by hypoxia; malnutrition of a pregnant woman; stress; smoking; alcohol; drugs that either directly pathologically affect the developing brain; or form a brain phenotype sensitive to a perinatal CNS affection. New data obliges to change the approaches to prevention of perinatal CNS affections.

Published
2016
Full Text
View/download PDF

2. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia

Author

Leonid M. Bardenstein, Ferenc Martenyi, Alexandr A. Yarosh, Irina Kozlova, Zykov Vp, Nikolay G. Neznanov, Natalia B. Jarkova, Petrukhin As, Nina K. Sukchotina, Olga I. Maslova, N. N. Zavadenko, and Victoria O. Soldatenkova

Subjects
Parents, Pediatrics, medicine.medical_specialty, Adolescent, Nausea, Atomoxetine Hydrochloride, Placebo, Russia, law.invention, Double-Blind Method, Randomized controlled trial, law, Weight Loss, Developmental and Educational Psychology, medicine, Humans, Attention deficit hyperactivity disorder, Child, Psychiatry, Psychiatric Status Rating Scales, Analysis of Variance, Adrenergic Uptake Inhibitors, Propylamines, Atomoxetine, General Medicine, medicine.disease, Abdominal Pain, Anorexia, Psychiatry and Mental health, Treatment Outcome, Tolerability, Attention Deficit Disorder with Hyperactivity, Pediatrics, Perinatology and Child Health, Female, medicine.symptom, Sleep, Psychology, Somnolence, Atomoxetine hydrochloride, medicine.drug
Abstract

The objective of the study was to compare the efficacy and tolerability of once-daily atomoxetine (or =1.8 mg/(kg day) with those of placebo in children and adolescents (aged 6-16 years) with attention-deficit/hyperactivity disorder [ADHD (DSM-IV)]. This randomized, placebo-controlled, double-blind trial was conducted in Russia. The primary efficacy measure was baseline-to-end point changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) total score. Tolerability measures included treatment-emergent signs and symptoms (TESS), laboratory values and weight. Compared with patients in the placebo group (n = 33), patients treated with atomoxetine (n = 72) with a mean final dose of 1.4 mg/kg showed significantly greater improvement in ADHDRS-IV-Parent:Inv total score (least-squares mean: atomoxetine, -15.8; placebo, -11.4; p = 0.013). The most common TESS in the atomoxetine group included anorexia [atomoxetine, n = 13 (18.1%); placebo, n = 2 (6.1%)], somnolence, n = 11 versus n = 3 (15.3% vs. 9.1%, respectively), abdominal pain n = 9 versus n = 1 (12.5% vs. 3.0%, respectively) and nausea, n = 8 versus n = 1 (11.1% vs. 3.0%, respectively). Seven patients in the atomoxetine group and two in the placebo group experienced clinically important weight loss during the study (or =7% from baseline; mean change, kg: atomoxetine, -0.6; placebo, 0.1; p = 0.032). Atomoxetine is efficacious in improving ADHD symptoms in children and adolescents. Atomoxetine treatment may be associated with a numerically higher incidence of anorexia, somnolence, abdominal pain and nausea, as well as statistically greater losses in body weight.

Published
2009
Full Text
View/download PDF

3. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver

Author

Svetlana Boiko, Olga Bikova, Alexei N. Boiko, Eugin Gusev, Donald W. Paty, Galina Vorobeichik, Olga I. Maslova, and Maria Guseva

Subjects
Adult, Male, Multiple Sclerosis, Optic Neuritis, Adolescent, Ancient history, Moscow, Severity of Illness Index, Galina, Medicine, Humans, Prospective Studies, Age of Onset, Child, Early onset, British Columbia, business.industry, General Medicine, Prognosis, Natural history, Child, Preschool, Sensation Disorders, Disease Progression, Surgery, Female, Neurology (clinical), business, Brain Stem
Abstract

data from Moscow and Vancouver Eugin Gusev , Alexei Boiko *, Olga Bikova , Olga Maslova , Maria Guseva , Svetlana Boiko , Galina Vorobeichik , Donald Paty c a Russian State Medical University, Baikalskaya 40/17, Apartment 277, Moscow 107207, Russia b Paediatric Institute of the Russian Academy of Medical Sciences, Moscow, Russia c Division of Neurology and MS Clinic, University of British Columbia, Vancouver, BC, Canada

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results